GSK momentum continues with strong start to 2023
For media and investors only
Issued: London, UK
Q1 2023 performance highlights
Sales performance reflected lower COVID-19 solutions sales versus Q1 2022. Excluding COVID-19 solutions, sales grew +10% CER with strong performance across Vaccines,...
Zur Pressemeldung auf www.gsk.com